Felzartamab in Antibody-Mediated Rejection

IF 96.2 1区医学 Q1 MEDICINE, GENERAL & INTERNAL

New England Journal of Medicine Pub Date : 2024-09-26 DOI:10.1056/nejmc2409970

引用次数: 0

Abstract

To the Editor: The trial by Böhmig and colleagues (July 11 issue)1 of felzartamab for the treatment of antibody-mediated rejection in kidney allografts showed promising results. However, notable li...

查看原文本刊更多论文

非扎他单抗在抗体介导的排斥反应中的应用

致编辑Böhmig及其同事（7月11日刊）1用非扎他单抗治疗肾脏异体移植中抗体介导的排斥反应的试验结果很有希望。然而，值得注意的是，该试验的结果并不理想。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

New England Journal of Medicine 医学-医学：内科

CiteScore

145.40

自引率

0.60%

发文量

1839

审稿时长

1 months

期刊介绍： The New England Journal of Medicine (NEJM) stands as the foremost medical journal and website worldwide. With an impressive history spanning over two centuries, NEJM boasts a consistent publication of superb, peer-reviewed research and engaging clinical content. Our primary objective revolves around delivering high-caliber information and findings at the juncture of biomedical science and clinical practice. We strive to present this knowledge in formats that are not only comprehensible but also hold practical value, effectively influencing healthcare practices and ultimately enhancing patient outcomes.